Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy ; volume:13 ; number:1 ; day:24 ; month:10 ; year:2014 ; pages:1-16 ; date:12.2014
Molecular cancer ; 13, Heft 1 (24.10.2014), 1-16, 12.2014
- Urheber
-
Iida, Mari
Brand, Toni M.
Starr, Megan M.
Huppert, Evan J.
Luthar, Neha
Bahrar, Harsh
Coan, John P.
Pearson, Hannah E.
Salgia, Ravi
Wheeler, Deric L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-13-242
- URN
-
urn:nbn:de:101:1-2019102719422206570684
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iida, Mari
- Brand, Toni M.
- Starr, Megan M.
- Huppert, Evan J.
- Luthar, Neha
- Bahrar, Harsh
- Coan, John P.
- Pearson, Hannah E.
- Salgia, Ravi
- Wheeler, Deric L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells